How can TAVI benefit your low-risk patients with severe aortic stenosis (sAS) now and in the future?

Supported by proven results from PARTNER 3,1 low-risk patients with sAS now have the opportunity for TAVI. As these patients are usually younger and healthier than those in higher risk categories,1-6 further considerations for this group include valve durability and valve-in-valve (ViV) procedures that support their longer-term management.

Now you can give your low-risk AS patients a chance at the lowest-risk option

Low risk patients are younger and healthier and, for them, sAS is their primary concern

Low-risk patients are healthier1

Low-risk patients are younger1

Low-risk patients have fewer comorbidities

Baseline patient characteristics of AS treated populations
Low-risk
PARTNER 3 Trial(n=950)
Intermediate-risk
PARTNER IIA Trial (n=938)
High-risk
PARTNER IA Trial (n=657)
NYHA Class III / IV
27.7%1
76.7%2
94.5%3
KCCQ Score
70.24
54.15
41.86
CAD
27.8%1
67.8%2
75.9%3
Previous CABG
2.4%7
24.6%2
43.3%3
COPD
5.6%1
30.8%2
43.7%3
Permanent PPM
2.6%1
11.8%2
21.2%3

CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; KCCQ, Kansas City Cardiomyopathy Questionnaire; NYHA, New York Heart Association; PPM, permanent pacemaker; STS, Society of Thoracic Surgeons.

Only SAPIEN 3 TAVI was proven superior to surgery on the primary endpoints (all-cause death, all-stroke, or rehospitalisation)1, 7

PARTNER 3 Low-Risk Trial

Primary Endpoint: Baseline Death, Stroke or Rehospitalisation

Change from baseline in KCCQ-OS score at 1 month, 6 months and 1 year with SAPIEN 3 TAVI 4

KCCQ-OS, Kansas City Cardiomyopathy Questionnaire–Overall Summary.

Proven to be superior to surgery on primary end points in PARTNER 3, refer your low-risk patients with sAS for TAVI evaluation

Valve durability and future treatment options are a key consideration in low-risk patients with sAS and longer life expectancies8-10

Especially in younger and healthier AS patients, valve durability and future treatment options should be considered.

Keep your low-risk patients active with a TAVI that is supported by real-world durability data

No matter what their future brings, know they have the option of ViV TAVI

        The PARTNER 3 Trial proved SAPIEN 3 TAVI is superior to surgery for the primary endpoint and multiple pre-specified secondary endpoints.1
1 month = 16.0 points; 95% CI 14.2 to 17.8; p<0.001. 6 months = 2.6 points; 95% CI 1.0 to 4.3; p=0.002. 1 year = 1.8 points; 95% CI 0.1 to 3.5; p=0.033.4
45.9mmHg at baseline, 11.6mmHg at 1 Year, 11.6mmHg at 3 Years and 11.2mmHg at 5 Years. 11
1.3% vs 0.8% for TAVI and sAVR, respectively. Odds ratio 0.60 (95% CI, 0.22-1.65; p = 0.31)11
0.63% vs 0.60% for rate of Stage 2 & 3 for TAVI and sAVR, respectively; p = 0.86. Stage 2 & 3 HVD defined as: + Δ mean gradient ≥ 10 mmHg and -Δ AVA ≥ 0.3 cm² or ≥ 25%, -Δ DVI ≥ 0.1 or ≥ 20%, AND/OR ≥ 1 grade Δ transvalvular AR with final grade ≥ moderate.11
0.63% vs 0.37% for TAVI and sAVR, respectively; p = 0.22. Bioprosthetic valve failure defined as: Re-intervention or death related to valve dysfunction, or severe (Stage 3) structural valve deterioration-related HVD.11

Check our latest articles

Tavi podcast series
Podcast Episode 4 – Benchmarking Efficiencies, Pre, Peri and Post TAVI Procedure
Jul 2021 Read more
Tavi podcast series
Podcast Episode 3 – The Collaborative Referral
Jun 2021 Read more

Stay informed with our newsletter

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.     Read more

References

  • 1Mack MJ, et al. N Engl J Med. 2019;380(18):1695—1705 and supplementary material.
  • 2Leon MB, et al. N Engl J Med 2016;374:1609—1620 and supplementary material.
  • 3Smith CR et al. N Engl J Med 2011;364:2187—2198 and supplementary material.
  • 4Baron SJ, et al. J Am Coll Cardiol. 2019;74(23):2833—2842.
  • 5Baron SJ, et al. JACC Cardiovascr Interv. 2018;11(12):1188—1198.
  • 6Reynolds MR, et al. J Am Coll Cardiol 2012;60(6):548—558.
  • 7Leon MB & Mack MJ. PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 17, 2019.
  • 8Rodriquez-Gabella T, et al. J Am Coll Cardiol. 2017;70(8):1013—1028.
  • 9Kuck K, et al. Cardiologist 2020;14: 182—204.
  • 10Sathananthan J, et al. Catheter Cardiovasc Interv. 2021;97(3):E431—E437.
  • 11Kodali SK, et al. Presentation at the Transcatheter Valve Therapies (TVT) Summit virtual event: TVT Connect 2020. Available at:
    https://www.tctmd.com/slide/sapien-3-transcatheter-aortic-valve-replacement-compared-surgery-intermediate-risk-patients-0 (accessed March 2021).
  • 12Silaschi M et al. Interactive Cardiovasc Thorac Surg. 2017;24(1):63—70.
  • 13Tam DY, et al. JACC Cardiovasc Interv. 2020;13(6):765—774.

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.

Skip to content